CompletedNCT00518232
Switching children with ADHD to extended-release methylphenidate
About this title
Read the official source —Medication studyAges 6–19
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 19 years. Other eligibility criteria applied.
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 520
- Sponsor
- Johnson & Johnson Taiwan Ltd
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Not clearly listed
- Age range
- From 6 Years to 19 Years
- Official registry ID
- NCT00518232
- Official title
Show the full official title
The Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS-Methylphenidate
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Johnson & Johnson Taiwan Ltd.
Did this study involve medication?
Yes. The study involved medication, including OROS-methylphenidate.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 19 years. Other eligibility criteria applied.
